Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

There we have it, Green Day. Well done to all at Cronos Australia. Great business Model, great team, more doctors and more pharmacy.

I believe now or in the near future some shares will need to be sold up, not down by the big share holders, to let other players in. Share price want move, unless this happens. Tight knit at the moment. IMO. But a Big BUY ATM.

“As the only profitable pure-play medicinal cannabis company listed on the ASX, we have achievedanother record quarter with $18 million in cash receipts and year-to-date positive operating cashflows of $10.5 million which is underpinned by the successful merger and integration with CDA Health and the hard work of our exceptional team. We enter the last quarter of the 2022 financial year in a position of market leadership in Australia with more than $13.6 million in cash and look forward to delivering for shareholders with our full year results. Our strategy moving into the 2023 financial year sets Cronos Australia up for sustainable, profitable growth,” said Cronos Australia CEO Rodney Cocks.